GoAI
Get started
Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$346.58

+$9.56 · +2.84%

Aug 21, 4:00 PM ET

KRYS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

80

Undervalued

Momentum

78

Gaining

Sentiment

50

Mixed

Risk resilience

78

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Krish S. Krishnan
Listed since
Sep 20, 2017
Employees
295

Market position

Day range

Current $346.58

52-week range

Current $346.58

Open
$337.44
Previous close
$337.02
Volume
407.81K
1.08× average
Average volume
376.13K
Average daily volume
Market cap
10.22B USD
Beta
0.54
Market reference 1
50-day average
$345.35
+0.36% above average
200-day average
$282.49
+22.69% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
6.65B USD
P/E (TTM)
41.91×
P/B (TTM)
7.53×
P/S (TTM)
23.2×
EV / EBITDA
33.92×
Earnings yield
2.87%
Free cash flow yield
2.65%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
93.34%
Operating margin
44.93%
Net margin
54.82%
Return on equity
16.80%
Return on assets
15.36%
Return on invested capital
13.09%

Financial health

Debt / equity
0.01×
Current ratio
9.95×
Altman Z-score
44.95
Piotroski F-score
5 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends125%1%-123%-247%Gross margin, FY2023: 93.90%Gross margin, FY2024: 93.09%Gross margin, FY2025: 92.61%Operating margin, FY2023: -216.43%Operating margin, FY2024: 22.61%Operating margin, FY2025: 41.45%Net margin, FY2023: 21.56%Net margin, FY2024: 30.69%Net margin, FY2025: 52.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2023 93.90%. Gross margin FY2024 93.09%. Gross margin FY2025 92.61%. Operating margin FY2023 -216.43%. Operating margin FY2024 22.61%. Operating margin FY2025 41.45%. Net margin FY2023 21.56%. Net margin FY2024 30.69%. Net margin FY2025 52.64%.

Income trends

Revenue

389.13M USD+33.94%

Operating income

161.3M USD+145.52%

Net income

204.83M USD+129.74%
Income trends across reported periods442.56M USD228.83M USD15.1M USD−198.63M USDRevenue, FY2023: 50.7M USDRevenue, FY2024: 290.52M USDRevenue, FY2025: 389.13M USDOperating income, FY2021: −68.28M USDOperating income, FY2022: −145.2M USDOperating income, FY2023: −109.73M USDOperating income, FY2024: 65.7M USDOperating income, FY2025: 161.3M USDNet income, FY2021: −69.57M USDNet income, FY2022: −139.98M USDNet income, FY2023: 10.93M USDNet income, FY2024: 89.16M USDNet income, FY2025: 204.83M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2023 50.7M USD. Revenue FY2024 290.52M USD. Revenue FY2025 389.13M USD. Operating income FY2021 −68.28M USD. Operating income FY2022 −145.2M USD. Operating income FY2023 −109.73M USD. Operating income FY2024 65.7M USD. Operating income FY2025 161.3M USD. Net income FY2021 −69.57M USD. Net income FY2022 −139.98M USD. Net income FY2023 10.93M USD. Net income FY2024 89.16M USD. Net income FY2025 204.83M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue389.13M USD290.52M USD50.7M USD——
Cost of goods sold28.77M USD20.06M USD3.09M USD——
Gross profit360.36M USD270.45M USD47.61M USD——
Research and development58.05M USD53.57M USD46.43M USD42.46M USD27.88M USD
Selling, general, and administrative146.74M USD113.69M USD98.4M USD77.74M USD40.39M USD
Operating expenses199.06M USD204.76M USD157.33M USD145.2M USD68.28M USD
Interest income28.18M USD29.66M USD22.62M USD5.22M USD197K USD
Interest expense————1.49M USD
Depreciation and amortization6.55M USD6.71M USD5.91M USD3.39M USD1.85M USD
Operating income161.3M USD65.7M USD−109.73M USD−145.2M USD−68.28M USD
Net income204.83M USD89.16M USD10.93M USD−139.98M USD−69.57M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+27.66%
11 comparable reports
Latest EPS result
1.79
Estimate 1.7 · Beat by 5.29%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.792.181.560.95Q1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 1.52, estimate 1.29, surprise +17.83%, Beat. Q2 2025, reported May 6, 2025: actual 1.2, estimate 1.38, surprise -13.04%, Miss. Q3 2025, reported Aug 4, 2025: actual 1.29, estimate 1.08, surprise +19.44%, Beat. Q4 2025, reported Nov 3, 2025: actual 2.66, estimate 1.12, surprise +137.50%, Beat. Q1 2026, reported Feb 17, 2026: actual 1.7, estimate 1.62, surprise +4.94%, Beat. Q2 2026, reported May 4, 2026: actual 1.83, estimate 1.45, surprise +26.21%, Beat. Q3 2026, reported Aug 3, 2026: actual 1.79, estimate 1.7, surprise +5.29%, Beat. Q4 2026, reported Nov 2, 2026: actual —, estimate 1.91, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates134.83M117.55M100.28M83MQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 19, 2025: actual 91.14M USD, estimate 91.35M USD, surprise -0.23%, Miss. Q2 2025, reported May 6, 2025: actual 88.18M USD, estimate 105.98M USD, surprise -16.79%, Miss. Q3 2025, reported Aug 4, 2025: actual 96.04M USD, estimate 95.41M USD, surprise +0.66%, Beat. Q4 2025, reported Nov 3, 2025: actual 97.8M USD, estimate 105.3M USD, surprise -7.12%, Miss. Q1 2026, reported Feb 17, 2026: actual 107.11M USD, estimate 105.35M USD, surprise +1.67%, Beat. Q2 2026, reported May 4, 2026: actual 116.36M USD, estimate 112.11M USD, surprise +3.79%, Beat. Q3 2026, reported Aug 3, 2026: actual 119.22M USD, estimate 120.93M USD, surprise -1.41%, Miss. Q4 2026, reported Nov 2, 2026: actual —, estimate 129.65M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$383.75

10.72% upside
Past 12 months12-month forecastHigh $474Average $383.75Low $300

Rating distribution

17 ratings
Strong buy00%
Buy17100%
Hold00%
Sell00%
Strong sell00%

Recent analyst actions

11 institutions
JefferiesmaintainBuy

KRYS news

247wallst.com

Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names like Wayfair, Roku, and Fox Corporation, while cooler inflation data reshuffled bets across stocks, bonds, oil, and…

Read source
zacks.com

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

Read source
seekingalpha.com

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for…

Read source
zacks.com

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.

Read source
globenewswire.com

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the…

Read source

KRYS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding KRYS

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Core S&P Mid-Cap ETF logoiShares Core S&P Mid-Cap ETFIJH
Market value
304.73M
Weight
0.24%
AUM
125.92B USD
Expense ratio
0.05%
Price / 1D
$76.77+0.52%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
304.43M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
223.98M
Weight
0.28%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
219.54M
Weight
0.12%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$304.76+0.64%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
127.1M
Weight
0.28%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$358.65+0.70%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
112.56M
Weight
0.99%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
103.01M
Weight
0.11%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
81.92M
Weight
0.55%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%

Continue in GoAI

Research KRYS

research.disclaimer